Select the Best Cancer Treatment Options with Positive Select
Despite all the breakthrough medical innovations made in recent times in terms of cancer care, yet the fear looms high when we hear that someone is ailing with cancer disease. Working towards this cause and easing out the testing procedure, Positive Bioscience has come up with Positive Select, a RNA sequencing test for Cancer treatment. Positive Select is the latest arsenal in fighting against cancer and is intended to aid Oncologists select the best treatment for cancer patients.
Positive Select is based on whole RNA sequencing which is the latest technology that enhances the utility of comprehensive genomics profile manifold bringing Genomics test closer to clinical practice. With this Positive Bioscience becomes the first company in India to offer whole RNA sequencing test commercially for cancer.
Positive Select is a comprehensive genomic solution for solid tumours(Lung Cancer, breast Cancer, Ovarian Cancer, Prostate Cancer, Sarcoma etc) as well as Haematological cancers(leukaemia, lymphoma, myeloma) designed to provide oncologists with clinically actionable report which can identify the molecular alterations in a patient’s tumour and match those alterations with relevant targeted therapies and clinical trials.
The test employs RNA sequencing to detect all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations and rearrangements, and gene fusions.Positive Select test results are provided in an easy-to-interpret report supported by a comprehensive review of published literature. Report provides treatment options with best probability of working in a particular patient based on cancer driving pathways and information on on-going clinical trials.
Announcing the launch of Positive Select recently Mr Samarth Jain, Chief Executive Officer, Positive Bioscience said: “Cancer is driven by genomic alterations. Positive Select detects genomic alterations in all 25,000 genes and recommends treatment options with best probability of response as compared to recommendations based on testing of 4-5 genes through conventional testing. We expect that Positive Select will revolutionise molecular diagnostics in a way CT scan revolutionised imaging diagnostics when X Ray was a norm.”